Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis

John M. McLaughlin(Pfizer (United States)), David L. Swerdlow(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Eric A. F. Simões(University of Colorado Hospital), Heinz‐Josef Schmitt(Pfizer (France)), Yasmeen Agosti(Pfizer (United States)), Farid Khan(Pfizer (United States))
The Journal of Infectious Diseases
December 18, 2020
10.1093/infdis/jiaa752
Cited by 113

Related Papers

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
|The Lancet|2017|2.4k
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
H1N1 2009 influenza virus infection during pregnancy in the USA
|The Lancet|2009|1.4k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k